JP2020517270A - ウィスコット・アルドリッチ症候群およびｘ連鎖性血小板減少症の治療的ゲノム編集 - Google Patents

ウィスコット・アルドリッチ症候群およびｘ連鎖性血小板減少症の治療的ゲノム編集 Download PDF

Info

Publication number
JP2020517270A
JP2020517270A JP2019557380A JP2019557380A JP2020517270A JP 2020517270 A JP2020517270 A JP 2020517270A JP 2019557380 A JP2019557380 A JP 2019557380A JP 2019557380 A JP2019557380 A JP 2019557380A JP 2020517270 A JP2020517270 A JP 2020517270A
Authority
JP
Japan
Prior art keywords
cells
cell
nuclease
vector
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019557380A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517270A5 (enExample
Inventor
ローリングス，デイヴィッド，ジェイ．
カーン，イラム
Original Assignee
シアトル チルドレンズ ホスピタル， ディービーエー シアトル チルドレンズ リサーチ インスティテュート
シアトル チルドレンズ ホスピタル， ディービーエー シアトル チルドレンズ リサーチ インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シアトル チルドレンズ ホスピタル， ディービーエー シアトル チルドレンズ リサーチ インスティテュート, シアトル チルドレンズ ホスピタル， ディービーエー シアトル チルドレンズ リサーチ インスティテュート filed Critical シアトル チルドレンズ ホスピタル， ディービーエー シアトル チルドレンズ リサーチ インスティテュート
Publication of JP2020517270A publication Critical patent/JP2020517270A/ja
Publication of JP2020517270A5 publication Critical patent/JP2020517270A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019557380A 2017-04-21 2018-04-19 ウィスコット・アルドリッチ症候群およびｘ連鎖性血小板減少症の治療的ゲノム編集 Pending JP2020517270A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762488249P 2017-04-21 2017-04-21
US62/488,249 2017-04-21
PCT/US2018/028442 WO2018195360A1 (en) 2017-04-21 2018-04-19 Therapeutic genome editing in wiskott-aldrich syndrome and x-linked thrombocytopenia

Publications (2)

Publication Number Publication Date
JP2020517270A true JP2020517270A (ja) 2020-06-18
JP2020517270A5 JP2020517270A5 (enExample) 2021-06-10

Family

ID=63856121

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019557380A Pending JP2020517270A (ja) 2017-04-21 2018-04-19 ウィスコット・アルドリッチ症候群およびｘ連鎖性血小板減少症の治療的ゲノム編集

Country Status (7)

Country Link
US (2) US11643671B2 (enExample)
EP (1) EP3612194A4 (enExample)
JP (1) JP2020517270A (enExample)
CN (1) CN110785179A (enExample)
AU (2) AU2018254529B2 (enExample)
CA (1) CA3060570A1 (enExample)
WO (1) WO2018195360A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018254529B2 (en) * 2017-04-21 2024-03-28 Seattle Children's Hospital (dba Seattle Children's Research Institute) Therapeutic genome editing in Wiskott-Aldrich syndrome and X-linked thrombocytopenia
WO2020150499A1 (en) * 2019-01-16 2020-07-23 Fred Hutchinson Cancer Research Center Methods to tag and isolate cells infected with the human immunodeficiency virus
EP4034641A4 (en) * 2019-09-26 2024-01-03 NantBio, Inc. PRIMARY T-CELL EXPANSION
US20220387528A1 (en) * 2019-11-11 2022-12-08 The Regents Of The University Of California Lentiviral vectors in hematopoietic stem cells to treat wiskott-aldrich syndrome (was)
CN111808859B (zh) * 2020-07-13 2022-09-13 中国科学院广州生物医药与健康研究院 WAS基因的gRNA及其应用
CN115927585B (zh) * 2022-08-29 2024-04-23 湖南家辉生物技术有限公司 WAS致病突变基因及在制备Wiskott-Aldrich综合征诊断试剂盒中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7582738B2 (en) * 2004-12-17 2009-09-01 Children's Hospital Medical Center Diagnostic assay for Wiskott-Aldrich syndrome and genetically related disorders
WO2015048577A2 (en) * 2013-09-27 2015-04-02 Editas Medicine, Inc. Crispr-related methods and compositions
DK3441468T3 (da) 2013-10-17 2021-07-26 Sangamo Therapeutics Inc Afgivelsesfremgangsmåder og sammensætninger til nukleasemedieret genom-manipulation
AU2015330699B2 (en) * 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
US10968253B2 (en) * 2015-10-20 2021-04-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and products for genetic engineering
EP3516058A1 (en) * 2016-09-23 2019-07-31 Casebia Therapeutics Limited Liability Partnership Compositions and methods for gene editing
US20200206322A1 (en) * 2017-03-21 2020-07-02 Stitch Bio, Llc Treating cancer with cas endonuclease complexes
AU2018254529B2 (en) * 2017-04-21 2024-03-28 Seattle Children's Hospital (dba Seattle Children's Research Institute) Therapeutic genome editing in Wiskott-Aldrich syndrome and X-linked thrombocytopenia
KR20210005178A (ko) 2018-04-27 2021-01-13 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 X-연관 고 igm 증후군에서의 치료적 게놈 편집
CA3098435A1 (en) * 2018-04-27 2019-10-31 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Talen-based and crispr/cas-based gene editing for bruton's tyrosine kinase
US11521964B2 (en) 2018-06-29 2022-12-06 Intel Corporation Schottky diode structures and integration with III-V transistors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MOLECULAR THERAPY,2016,24(SUPPL1),S227, JPN6022014579, ISSN: 0004970674 *
NUCLEIC ACIDS RES.,2017,45(5),E29,P.1-12, JPN6022014576, ISSN: 0004970675 *

Also Published As

Publication number Publication date
AU2024204421A1 (en) 2024-07-18
EP3612194A1 (en) 2020-02-26
US20240141389A1 (en) 2024-05-02
AU2018254529B2 (en) 2024-03-28
WO2018195360A1 (en) 2018-10-25
CN110785179A (zh) 2020-02-11
US20200325494A1 (en) 2020-10-15
US11643671B2 (en) 2023-05-09
AU2018254529A1 (en) 2019-11-07
EP3612194A4 (en) 2020-12-30
WO2018195360A8 (en) 2019-06-13
CA3060570A1 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
US20250179146A1 (en) Genetically engineered t cells with regnase-1 and/or tgfbrii disruption have improved functionality and persistence
US12398193B2 (en) Targeted replacement of endogenous T cell receptors
JP2020517270A (ja) ウィスコット・アルドリッチ症候群およびｘ連鎖性血小板減少症の治療的ゲノム編集
JP2021521855A (ja) ヘモグロビン関連変異の編集のための相同組換え修復用鋳型の設計およびその送達
US11118195B2 (en) Universal donor cells
US20230346836A1 (en) Genetically engineered t cells with disrupted casitas b-lineage lymphoma proto-oncogene-b (cblb) and uses thereof
US11578309B2 (en) Universal donor cells
KR20250068649A (ko) 공동 발현된 tgfbr shrna를 갖는 면역 세포
JP2025522812A (ja) Ｇｐｃ－３を標的とするキメラ抗原受容体、及び治療的使用目的でそのようなキメラ抗原受容体を発現する免疫細胞

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210419

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220419

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220706

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221017

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230124